These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 12384919)

  • 1. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.
    Garnero P; Ayral X; Rousseau JC; Christgau S; Sandell LJ; Dougados M; Delmas PD
    Arthritis Rheum; 2002 Oct; 46(10):2613-24. PubMed ID: 12384919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N; Juillet F; Garnero P
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations.
    Rousseau JC; Chevrel G; Schott AM; Garnero P
    Bone; 2010 Apr; 46(4):897-900. PubMed ID: 20005316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides.
    Christensen AF; Hørslev-Petersen K; Christgau S; Lindegaard HM; Lottenburger T; Junker K; Hetland ML; Stengaard-Pedersen K; Jacobsen S; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Pødenphant J; Heegaard NH; Vestergaard A; Jurik AG; Ostergaard M; Junker P
    J Rheumatol; 2010 Jun; 37(6):1113-20. PubMed ID: 20436079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of serum markers of cartilage metabolism to imaging and clinical outcome measures of knee joint structure.
    Berry PA; Maciewicz RA; Wluka AE; Downey-Jones MD; Forbes A; Hellawell CJ; Cicuttini FM
    Ann Rheum Dis; 2010 Oct; 69(10):1816-22. PubMed ID: 20551154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis--association with disease progression.
    Sharif M; Kirwan J; Charni N; Sandell LJ; Whittles C; Garnero P
    Rheumatology (Oxford); 2007 Jun; 46(6):938-43. PubMed ID: 17387119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal relationship between serum adipokines, biomarkers of bone and cartilage turnover, and cartilage volume loss in a population with clinical knee osteoarthritis.
    Berry PA; Jones SW; Cicuttini FM; Wluka AE; Maciewicz RA
    Arthritis Rheum; 2011 Mar; 63(3):700-7. PubMed ID: 21305502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years.
    Sharif M; Kirwan JR; Elson CJ; Granell R; Clarke S
    Arthritis Rheum; 2004 Aug; 50(8):2479-88. PubMed ID: 15334461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers.
    Cibere J; Thorne A; Kopec JA; Singer J; Canvin J; Robinson DB; Pope J; Hong P; Grant E; Lobanok T; Ionescu M; Poole AR; Esdaile JM
    J Rheumatol; 2005 May; 32(5):896-902. PubMed ID: 15868627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study.
    Garnero P; Peterfy C; Zaim S; Schoenharting M
    Arthritis Rheum; 2005 Sep; 52(9):2822-9. PubMed ID: 16145678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type II collagen peptides for measuring cartilage degradation.
    Henrotin Y; Deberg M; Dubuc JE; Quettier E; Christgau S; Reginster JY
    Biorheology; 2004; 41(3-4):543-7. PubMed ID: 15299285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathobiology of focal lesion development in aging human articular cartilage and molecular matrix changes characteristic of osteoarthritis.
    Squires GR; Okouneff S; Ionescu M; Poole AR
    Arthritis Rheum; 2003 May; 48(5):1261-70. PubMed ID: 12746899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores.
    Wu CW; Morrell MR; Heinze E; Concoff AL; Wollaston SJ; Arnold EL; Singh R; Charles C; Skovrun ML; FitzGerald JD; Moreland LW; Kalunian KC
    Semin Arthritis Rheum; 2005 Dec; 35(3):197-201. PubMed ID: 16325660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does hand osteoarthritis predict future hip or knee osteoarthritis?
    Dahaghin S; Bierma-Zeinstra SM; Reijman M; Pols HA; Hazes JM; Koes BW
    Arthritis Rheum; 2005 Nov; 52(11):3520-7. PubMed ID: 16255023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis.
    Jung M; Christgau S; Lukoschek M; Henriksen D; Richter W
    Pathobiology; 2004; 71(2):70-6. PubMed ID: 14707441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage.
    Garnero P; Piperno M; Gineyts E; Christgau S; Delmas PD; Vignon E
    Ann Rheum Dis; 2001 Jun; 60(6):619-26. PubMed ID: 11350852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: data from MOKHA study.
    Henrotin Y; Bannuru R; Malaise M; Ea HK; Confavreux C; Bentin J; Urbin-Choffray D; Conrozier T; Brasseur JP; Thomas P; Hick AC; Marinello A; Giordan N; Richette P
    BMC Musculoskelet Disord; 2019 Jun; 20(1):293. PubMed ID: 31215422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis.
    Rousseau JC; Zhu Y; Miossec P; Vignon E; Sandell LJ; Garnero P; Delmas PD
    Osteoarthritis Cartilage; 2004 Jun; 12(6):440-7. PubMed ID: 15135140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis.
    Lohmander LS; Yoshihara Y; Roos H; Kobayashi T; Yamada H; Shinmei M
    J Rheumatol; 1996 Oct; 23(10):1765-9. PubMed ID: 8895155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.